Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KDM5C | P41229 | 1/20 | 0.44 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1534041 | 1.00 | CTSD (0.44) | CTSDKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL1534035 | 1.00 | CTSD (0.44) | CTSDKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL28845044 | 0.87 | CTSD (0.41) | CTSDKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL8495405 | 0.85 | ALDH1A1 (0.44) | CTSDKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL29833669 | 0.82 | BLM (0.58) | HIF1ACYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL288407 | 0.82 | BLM (0.58) | HIF1ACYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL10135850 | 0.82 | GSR (0.60) | CTSDKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL11215138 | 0.82 | GSR (0.60) | CTSDKDM4EKDM5CPHF8KDM2A | |
| SCHEMBL709483 | 0.82 | GRM8 (0.60) | KDM4EKDM5CPHF8KDM2ACYP1A2 | |
| SCHEMBL709482 | 0.82 | GRM8 (0.60) | KDM4EKDM5CPHF8KDM2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189392-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240182580-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240139285-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | SUTRO BIOPHARMA INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-11958909-B2 | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240058467-A1 | ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20240058465-A1 | ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-1718339-A2 | MODIFIED HUMAN INTERFERON POLYPEPTIDES AND THEIR USES | Ambrx, Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006091231-A2 | BIOSYNTHETIC POLYPEPTIDES UTILIZING NON-NATURALLY ENCODED AMINO ACIDS | AMBRX, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060189529-A1 | Linked to polyoxyethylene glycol via oximination; improved half-life | AMBRX, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060153860-A1 | Novel antigen-binding polypeptides and their uses | AMBRX, INC. (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2006069220-A2 | MODIFIED HUMAN GROWTH HORMONE | AMBRX, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060019347-A1 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids | AMBRX, INC. (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2006009901-A2 | NOVEL ANTIGEN-BINDING POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005074524-A2 | MODIFIED HUMAN INTERFERON POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005074650-A2 | MODIFIED HUMAN FOUR HELICAL BUNDLE POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20050170404-A1 | Linked to water soluble polyoxyethylene glycol | AMBRX, INC. (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139285-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | CTSD 2131/4885KDM4E 4257/4885KDM5C 3476/4885 |
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | CTSD 1111/4885KDM4E 4627/4885KDM5C 3144/4885 |
| US-20240182580-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | CTSD 1111/4885KDM4E 4627/4885KDM5C 3144/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | CTSD 2561/4885KDM4E 3476/4885KDM5C 1830/4885 |
| US-11958909-B2 | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use | DNPEP, LNPEP, ANPEP | CTSD 3041/4885KDM4E 3513/4885KDM5C 2259/4885 |
| US-20060153860-A1 | Novel antigen-binding polypeptides and their uses | CD2BP2, CD74, LGALS3BP | CTSD 1511/4885KDM4E 4676/4885KDM5C 4599/4885 |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | CTSD 2711/4885KDM4E 4048/4885KDM5C 3327/4885 |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | CSF3R, GMFG, HDGF | CTSD 498/4885KDM4E 4840/4885KDM5C 4824/4885 |
| US-20060189529-A1 | Linked to polyoxyethylene glycol via oximination; improved half-life | GHRHR, VEGFA, SHBG | CTSD 3426/4885KDM4E 2835/4885KDM5C 2989/4885 |
| US-20060019347-A1 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids | NPEPPS, COASY, BCAT1 | CTSD 4218/4885KDM4E 4474/4885KDM5C 4063/4885 |
| US-20240058465-A1 | ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATES | ROR1, RORA, RORB | CTSD 4674/4885KDM4E 2934/4885KDM5C 2205/4885 |
| US-20240058467-A1 | ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATES | ROR1, RORA, RORB | CTSD 4674/4885KDM4E 2934/4885KDM5C 2205/4885 |
| US-20240189392-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP3 | CTSD 4044/4885KDM4E 3586/4885KDM5C 3194/4885 |
| US-20050170404-A1 | Linked to water soluble polyoxyethylene glycol | GHITM, HDGF, GHRHR | CTSD 2111/4885KDM4E 4762/4885KDM5C 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.